ABCC2 and chronic myelogenous leukemia, BCR-ABL1 positive: In the current study, we examined whether genetic polymorphisms in ABCB1, ABCC1, ABCC2, and ABCG2 genes may have an impact on the outcome of CML patients treated with nilotinib.